Table 3.
Odds of chronic kidney disease mineral and bone disorder medication prescription in Medicare Part D-enrolled dialysis patients with versus without low-income subsidy
| 2007 | 2008 | 2009 | 2010 | |
|---|---|---|---|---|
| Medication | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Phosphate binder | ||||
| Calcium acetate | 1.17 (1.14–1.19) | 1.20 (1.17–1.23) | 1.20 (1.17–1.22) | 1.17 (1.14–1.19) |
| Lanthanum carbonate | 1.24 (1.20–1.29) | 1.44 (1.39–1.50) | 1.63 (1.57–1.69) | 1.61 (1.55–1.67) |
| Sevelamer carbonate | - | 1.21 (1.15–1.27) | 1.16 (1.13–1.19) | 1.48 (1.45–1.52) |
| Sevelamer hydrochloride | 1.50 (1.47–1.54) | 1.60 (1.57–1.64) | 1.89 (1.85–1.93) | 2.33 (2.26–2.40) |
| Any agent | 1.60 (1.56–1.64) | 1.75 (1.71–1.79) | 1.91 (1.86–1.95) | 1.91 (1.87–1.95) |
| Oral Vitamin D analogue | ||||
| Calcitriol | 0.72 (0.69–0.76) | 0.70 (0.67–0.73) | 0.73 (0.70–0.76) | 0.75 (0.72–0.78) |
| Doxercalciferol | 0.79 (0.73–0.86) | 0.85 (0.79–0.92) | 0.96 (0.89–1.03)b | 0.95 (0.88–1.03)b |
| Paricalcitol | 0.74 (0.66–0.82) | 0.74 (0.67–0.81) | 0.78 (0.71–0.83) | 0.72 (0.67–0.78) |
| Any agent | 0.74 (0.71–0.77) | 0.73 (0.71–0.76) | 0.78 (0.75–0.80) | 0.77 (0.75–0.80) |
| IV Vitamin D analogue | ||||
| Calcitriol | 1.37 (1.26–1.49) | 1.19 (1.09–1.31) | 1.24 (1.13–1.370 | 1.34 (1.22–1.46) |
| Doxercalciferol | 1.48 (1.44–1.52) | 1.44 (1.40–1.48) | 1.46 (1.42–1.50) | 1.64 (1.60–1.68) |
| Paricalcitol | 1.66 (1.63–1.70) | 1.73 (1.70–1.77) | 1.76 (1.72–1.80) | 1.86 (1.82–1.90) |
| Any agent | 2.21 (2.16–2.27) | 2.28 (2.23–2.33) | 2.26 (2.21–2.31) | 2.38 (2.33–2.43) |
| Calcimimetic | ||||
| Cinacalcet | 1.44 (1.41–1.48) | 1.51 (1.47–1.55) | 1.53 (1.49–1.57) | 1.44 (1.41–1.48) |
Note: P values were < 0.001 unless stated otherwise. Odd ratios are calculated from a model including age, sex, race, dialysis vintage, and dialysis organization.
CI, confidence interval; IV, intravenous; OR, odds ratio.
b
P values were > 0.05.